Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Rapport Therapeutics, Inc. Common Stock (RAPP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RAPP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $34.2
1 Year Target Price $34.2
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.62% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 545.28M USD | Price to earnings Ratio 12.45 | 1Y Target Price 34.2 |
Price to earnings Ratio 12.45 | 1Y Target Price 34.2 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 6.43 - 29.74 | Updated Date 08/15/2025 |
52 Weeks Range 6.43 - 29.74 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.2 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.77 | Actual -0.75 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.14% | Return on Equity (TTM) -29.42% |
Valuation
Trailing PE 12.45 | Forward PE - | Enterprise Value 296694924 | Price to Sales(TTM) - |
Enterprise Value 296694924 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 36497900 | Shares Floating 14951373 |
Shares Outstanding 36497900 | Shares Floating 14951373 | ||
Percent Insiders 6.28 | Percent Institutions 106.26 |
Upturn AI SWOT
Rapport Therapeutics, Inc. Common Stock
Company Overview
History and Background
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for central nervous system (CNS) disorders. Founded in 2022, it focuses on leveraging insights into the structural biology of G protein-coupled receptors (GPCRs) to create targeted therapies. Rapport Therapeutics had its IPO in June 2024.
Core Business Areas
- Precision Medicines for CNS Disorders: Rapport is creating a portfolio of selective, centrally acting small molecules targeting clinically validated GPCRs to address unmet needs in neurology and psychiatry.
Leadership and Structure
Rapport Therapeutics is led by CEO Ray Kelleher, M.D., Ph.D. The company has a scientific advisory board with expertise in GPCR biology, neuroscience, and drug development.
Top Products and Market Share
Key Offerings
- RAP-219: RAP-219 is Rapport's lead program, an EP2 receptor antagonist being developed for drug-resistant epilepsy. Phase 1 clinical trials are underway. Competitors in the epilepsy space include UCB, Eisai, and SK Biopharmaceuticals. Market share data specific to RAP-219 is not yet available as it is still in clinical development.
- GPCR Platform: Rapport's proprietary platform for discovering and developing selective GPCR-targeting medicines is a key asset. Competition comes from other biotechnology companies using similar approaches, as well as larger pharmaceutical firms with internal discovery capabilities.
Market Dynamics
Industry Overview
The CNS therapeutics market is large and growing, driven by increasing prevalence of neurological and psychiatric disorders. It is a highly competitive and regulated space.
Positioning
Rapport Therapeutics positions itself as a precision medicine company focused on developing highly selective GPCR-targeted therapies for CNS disorders, which differentiates it from companies developing broader spectrum or less targeted approaches.
Total Addressable Market (TAM)
The TAM for CNS therapeutics is estimated to be in the hundreds of billions of dollars. Rapport is targeting specific sub-segments within this large market, such as drug-resistant epilepsy, with a focus on developing first-in-class or best-in-class therapies.
Upturn SWOT Analysis
Strengths
- Proprietary GPCR-targeted drug discovery platform
- Experienced leadership team
- Strong financial backing from venture capital
- Focus on precision medicine approach
Weaknesses
- Early stage of development (clinical trials underway)
- High risk of clinical trial failure
- Dependence on key personnel and intellectual property
- Relatively small company size
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to address additional CNS disorders
- Positive clinical trial results
- Advancements in GPCR biology and drug discovery technologies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Unfavorable clinical trial results
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- UCB (UCBJF)
- Eisai (ESALY)
- SK Biopharmaceuticals (326030.KS)
Competitive Landscape
Rapport's competitive advantage lies in its proprietary GPCR-targeted drug discovery platform and its focus on precision medicine. However, it faces significant competition from larger, more established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth data available due to recent IPO.
Future Projections: Future growth is dependent on the success of clinical trials and the potential commercialization of RAP-219 and other pipeline programs. Analyst estimates are not yet widely available for Rapport.
Recent Initiatives: Recent initiatives include advancing RAP-219 into Phase 1 clinical trials and expanding the pipeline of GPCR-targeted drug candidates.
Summary
Rapport Therapeutics is an early-stage biotechnology company with a promising GPCR-targeted drug discovery platform. Its lead program, RAP-219, is in clinical development. The company's success hinges on positive clinical trial outcomes, successful pipeline expansion, and strategic partnerships. Key risks include clinical trial failures, competition, and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Rapport Therapeutics Investor Relations
- SEC Filings
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual research and consultation with a financial advisor. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rapport Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2024-06-07 | CEO, President, Treasurer & Director Mr. Abraham N. Ceesay M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://www.rapportrx.com |
Full time employees 69 | Website https://www.rapportrx.com | ||
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.